
June 16 (Reuters) - Supernus Pharmaceuticals Inc SUPN.O:
SUPERNUS PHARMACEUTICALS TO ACQUIRE SAGE THERAPEUTICS, STRENGTHENING ITS NEUROPSYCHIATRY PRODUCT PORTFOLIO
UPFRONT CASH PAYMENT OF $8.50 PER SHARE
EXPECTED TO BE SIGNIFICANTLY ACCRETIVE IN 2026 WITH POTENTIAL COST SYNERGIES OF UP TO $200 MILLION ON AN ANNUAL BASIS
DEALFOR AN AGGREGATE OF UP TO APPROXIMATELY $795 MILLION OR $12.00 PER SHARE
Further company coverage: SUPN.O